A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix

a Gynecologic Oncology Group study.

W. P. McGuire, J. Arseneau, J. A. Blessing, P. J. DiSaia, Kenneth D Hatch, F. T. Given, N. N. Teng, W. T. Creasman

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

A total of 394 patients with advanced, measurable squamous carcinoma of the uterine cervix and no prior chemotherapy were randomized to therapy with either carboplatin or iproplatin. There were 23 patients ineligible for the study and 10 patients who were not evaluable; the remaining 361 patients were evaluable for response and adverse effects. Randomization was well balanced for age, performance status, and prior therapy. Both platinum analogs were given every 28 days with starting doses of 400 mg/m2 for carboplatin (340 mg/m2 if the patient underwent prior radiation) and 270 mg/m2 for iproplatin (230 mg/m2 if the patient underwent prior radiation). These doses are equivalent to cisplatin doses of 75 to 100 mg/m2. Hematologic toxicity was dose-limiting, among which thrombocytopenia was slightly more common than leukopenia. Gastrointestinal toxicity was also prominent with both agents; however, iproplatin was significantly more toxic than carboplatin (P less than .001). Renal, otic, and peripheral nervous system toxicities were absent or infrequent with both analogs. No electrolyte abnormalities were observed. The percentage of planned dosages that were actually administered was 100% of carboplatin doses and 85% of iproplatin doses (P less than .0001). The reduction in iproplatin dose was apparently due to gastrointestinal toxicity. Response rates were similar for both agents (15% for carboplatin, 11% for iproplatin) and appear to be inferior to those noted with the parent compound, cisplatin.

Original languageEnglish (US)
Pages (from-to)1462-1468
Number of pages7
JournalJournal of Clinical Oncology
Volume7
Issue number10
StatePublished - Oct 1989
Externally publishedYes

Fingerprint

Carboplatin
Cervix Uteri
Squamous Cell Carcinoma
Cisplatin
Radiation
Poisons
Peripheral Nervous System
Leukopenia
Random Allocation
Platinum
Thrombocytopenia
Electrolytes
Ear
iproplatin
Kidney
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix : a Gynecologic Oncology Group study. / McGuire, W. P.; Arseneau, J.; Blessing, J. A.; DiSaia, P. J.; Hatch, Kenneth D; Given, F. T.; Teng, N. N.; Creasman, W. T.

In: Journal of Clinical Oncology, Vol. 7, No. 10, 10.1989, p. 1462-1468.

Research output: Contribution to journalArticle

McGuire, WP, Arseneau, J, Blessing, JA, DiSaia, PJ, Hatch, KD, Given, FT, Teng, NN & Creasman, WT 1989, 'A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study.', Journal of Clinical Oncology, vol. 7, no. 10, pp. 1462-1468.
McGuire, W. P. ; Arseneau, J. ; Blessing, J. A. ; DiSaia, P. J. ; Hatch, Kenneth D ; Given, F. T. ; Teng, N. N. ; Creasman, W. T. / A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix : a Gynecologic Oncology Group study. In: Journal of Clinical Oncology. 1989 ; Vol. 7, No. 10. pp. 1462-1468.
@article{09e115f6b93345849b655586770096d8,
title = "A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study.",
abstract = "A total of 394 patients with advanced, measurable squamous carcinoma of the uterine cervix and no prior chemotherapy were randomized to therapy with either carboplatin or iproplatin. There were 23 patients ineligible for the study and 10 patients who were not evaluable; the remaining 361 patients were evaluable for response and adverse effects. Randomization was well balanced for age, performance status, and prior therapy. Both platinum analogs were given every 28 days with starting doses of 400 mg/m2 for carboplatin (340 mg/m2 if the patient underwent prior radiation) and 270 mg/m2 for iproplatin (230 mg/m2 if the patient underwent prior radiation). These doses are equivalent to cisplatin doses of 75 to 100 mg/m2. Hematologic toxicity was dose-limiting, among which thrombocytopenia was slightly more common than leukopenia. Gastrointestinal toxicity was also prominent with both agents; however, iproplatin was significantly more toxic than carboplatin (P less than .001). Renal, otic, and peripheral nervous system toxicities were absent or infrequent with both analogs. No electrolyte abnormalities were observed. The percentage of planned dosages that were actually administered was 100{\%} of carboplatin doses and 85{\%} of iproplatin doses (P less than .0001). The reduction in iproplatin dose was apparently due to gastrointestinal toxicity. Response rates were similar for both agents (15{\%} for carboplatin, 11{\%} for iproplatin) and appear to be inferior to those noted with the parent compound, cisplatin.",
author = "McGuire, {W. P.} and J. Arseneau and Blessing, {J. A.} and DiSaia, {P. J.} and Hatch, {Kenneth D} and Given, {F. T.} and Teng, {N. N.} and Creasman, {W. T.}",
year = "1989",
month = "10",
language = "English (US)",
volume = "7",
pages = "1462--1468",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "10",

}

TY - JOUR

T1 - A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix

T2 - a Gynecologic Oncology Group study.

AU - McGuire, W. P.

AU - Arseneau, J.

AU - Blessing, J. A.

AU - DiSaia, P. J.

AU - Hatch, Kenneth D

AU - Given, F. T.

AU - Teng, N. N.

AU - Creasman, W. T.

PY - 1989/10

Y1 - 1989/10

N2 - A total of 394 patients with advanced, measurable squamous carcinoma of the uterine cervix and no prior chemotherapy were randomized to therapy with either carboplatin or iproplatin. There were 23 patients ineligible for the study and 10 patients who were not evaluable; the remaining 361 patients were evaluable for response and adverse effects. Randomization was well balanced for age, performance status, and prior therapy. Both platinum analogs were given every 28 days with starting doses of 400 mg/m2 for carboplatin (340 mg/m2 if the patient underwent prior radiation) and 270 mg/m2 for iproplatin (230 mg/m2 if the patient underwent prior radiation). These doses are equivalent to cisplatin doses of 75 to 100 mg/m2. Hematologic toxicity was dose-limiting, among which thrombocytopenia was slightly more common than leukopenia. Gastrointestinal toxicity was also prominent with both agents; however, iproplatin was significantly more toxic than carboplatin (P less than .001). Renal, otic, and peripheral nervous system toxicities were absent or infrequent with both analogs. No electrolyte abnormalities were observed. The percentage of planned dosages that were actually administered was 100% of carboplatin doses and 85% of iproplatin doses (P less than .0001). The reduction in iproplatin dose was apparently due to gastrointestinal toxicity. Response rates were similar for both agents (15% for carboplatin, 11% for iproplatin) and appear to be inferior to those noted with the parent compound, cisplatin.

AB - A total of 394 patients with advanced, measurable squamous carcinoma of the uterine cervix and no prior chemotherapy were randomized to therapy with either carboplatin or iproplatin. There were 23 patients ineligible for the study and 10 patients who were not evaluable; the remaining 361 patients were evaluable for response and adverse effects. Randomization was well balanced for age, performance status, and prior therapy. Both platinum analogs were given every 28 days with starting doses of 400 mg/m2 for carboplatin (340 mg/m2 if the patient underwent prior radiation) and 270 mg/m2 for iproplatin (230 mg/m2 if the patient underwent prior radiation). These doses are equivalent to cisplatin doses of 75 to 100 mg/m2. Hematologic toxicity was dose-limiting, among which thrombocytopenia was slightly more common than leukopenia. Gastrointestinal toxicity was also prominent with both agents; however, iproplatin was significantly more toxic than carboplatin (P less than .001). Renal, otic, and peripheral nervous system toxicities were absent or infrequent with both analogs. No electrolyte abnormalities were observed. The percentage of planned dosages that were actually administered was 100% of carboplatin doses and 85% of iproplatin doses (P less than .0001). The reduction in iproplatin dose was apparently due to gastrointestinal toxicity. Response rates were similar for both agents (15% for carboplatin, 11% for iproplatin) and appear to be inferior to those noted with the parent compound, cisplatin.

UR - http://www.scopus.com/inward/record.url?scp=0024747607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024747607&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 1462

EP - 1468

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 10

ER -